Literature DB >> 12757152

Overlap syndromes of autoimmune hepatitis: what is known so far.

Marilena Durazzo1, Alberto Premoli, Sharmila Fagoonee, Rinaldo Pellicano.   

Abstract

The pattern of some autoimmune hepatitis can be difficult to classify, sometimes due to the overlap of these with primary biliary cirrhosis, primary sclerosing cholangitis and chronic viral hepatitis. The etiology of these variant forms remains unclear. The distinction among the overlap syndromes poses different problems both of prognosis and therapeutic approach. Presently, the utility of the scoring system devised and revised by the International Autoimmune Hepatitis Group regarding these cases is under discussion. Histological examination seems to be an important tool, but often the result does not help in defining a correct diagnosis. To date, the overlap syndromes can be classified at an intermediate level between cholestatic forms of autoimmune hepatitis or hepatic forms of cholestatic syndromes, but it cannot be excluded that the syndromes represent independent disorders.

Entities:  

Mesh:

Year:  2003        PMID: 12757152     DOI: 10.1023/a:1022597210629

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  72 in total

1.  The natural history of primary biliary cirrhosis: of genes and cooperation.

Authors:  M E Gershwin
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease.

Authors:  M P Manns; P Obermayer-Straub
Journal:  Hepatology       Date:  1997-10       Impact factor: 17.425

Review 3.  Primary biliary cirrhosis.

Authors:  M M Kaplan
Journal:  N Engl J Med       Date:  1996-11-21       Impact factor: 91.245

4.  Strategies for assessing the long-term consequences of Hepatitis C virus infection.

Authors:  L B Seeff
Journal:  Minerva Gastroenterol Dietol       Date:  2000-12

5.  Antimitochondrial antibody-negative chronic nonsuppurative destructive cholangitis. Atypical primary biliary cirrhosis or autoimmune cholangitis?

Authors:  P Sánchez-Pobre; G Castellano; F Colina; P Dominguez; S Rodriguez; F Canga; J A Herruzo
Journal:  J Clin Gastroenterol       Date:  1996-10       Impact factor: 3.062

6.  Hepatocellular carcinoma in autoimmune hepatitis.

Authors:  S Z Park; D M Nagorney; A J Czaja
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

Review 7.  The journey from hepatitis to hepatocellular carcinoma. Bridging role of Helicobacter species.

Authors:  S Fagoonee; R Pellicano; M Rizzetto; A Ponzetto
Journal:  Panminerva Med       Date:  2001-12       Impact factor: 5.197

8.  [A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis)].

Authors:  G Brunner; O Klinge
Journal:  Dtsch Med Wochenschr       Date:  1987-09-18       Impact factor: 0.628

9.  Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.

Authors:  P Michieletti; I R Wanless; A Katz; P J Scheuer; S J Yeaman; M F Bassendine; J M Palmer; E J Heathcote
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

10.  An atypical presentation for primary sclerosing cholangitis.

Authors:  V A Luketic; D A Gomez; A J Sanyal; M L Shiffman
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

View more
  2 in total

1.  Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis.

Authors:  Michael Hunter; Maurice B Loughrey; Moyra Gray; Peter Ellis; Neil McDougall; Michael Callender
Journal:  Ulster Med J       Date:  2011-01

Review 2.  Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis.

Authors:  Yan Zhang; Jie Lu; Weiqi Dai; Fan Wang; Miao Shen; Jing Yang; Rong Zhu; Huawei Zhang; Kan Chen; Ping Cheng; Lei He; Chengfen Wang; Ling Xu; Yingqun Zhou; Chuanyong Guo
Journal:  Gastroenterol Res Pract       Date:  2013-12-04       Impact factor: 2.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.